{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:46:08Z","timestamp":1793245568208,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000924","name":"Multiple Sclerosis Australia","doi-asserted-by":"publisher","award":["22-3-052"],"award-info":[{"award-number":["22-3-052"]}],"id":[{"id":"10.13039\/501100000924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000924","name":"Multiple Sclerosis Australia","doi-asserted-by":"publisher","award":["21-2-060"],"award-info":[{"award-number":["21-2-060"]}],"id":[{"id":"10.13039\/501100000924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"DOI":"10.1186\/s12974-024-03263-9","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T10:04:05Z","timestamp":1730455445000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of alemtuzumab in the development of secondary autoimmunity in multiple sclerosis: a systematic review"],"prefix":"10.1186","volume":"21","author":[{"given":"Sofia","family":"Jimenez-Sanchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"Maksoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Eaton-Fitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Marshall-Gradisnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Broadley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"issue":"10422","key":"3263_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","volume":"403","author":"D Jakimovski","year":"2024","unstructured":"Jakimovski D, et al. Multiple sclerosis. Lancet. 2024;403(10422):183\u2013202.","journal-title":"Lancet"},{"issue":"1","key":"3263_CR2","doi-asserted-by":"publisher","first-page":"e1583","DOI":"10.1002\/wsbm.1583","volume":"15","author":"GM Mey","year":"2023","unstructured":"Mey GM, Mahajan KR, DeSilva TM. Neurodegeneration in multiple sclerosis. WIREs Mech Dis. 2023;15(1):e1583.","journal-title":"WIREs Mech Dis"},{"key":"3263_CR3","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a029025","author":"BJ Kaskow","year":"2018","unstructured":"Kaskow BJ, Baecher-Allan C. Effector T cells in multiple sclerosis. Cold Spring Harb Perspect Med. 2018. https:\/\/doi.org\/10.1101\/cshperspect.a029025.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"3263_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1080\/23328940.2018.1475831","volume":"5","author":"A Christogianni","year":"2018","unstructured":"Christogianni A, et al. Temperature sensitivity in multiple sclerosis: an overview of its impact on sensory and cognitive symptoms. Temperature (Austin). 2018;5(3):208\u201323.","journal-title":"Temperature (Austin)"},{"key":"3263_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011203.pub2","author":"R Riera","year":"2016","unstructured":"Riera R, Porf\u00edrio GJ, Torloni MR. Alemtuzumab for multiple sclerosis. Cochrane Database Syst Rev. 2016. https:\/\/doi.org\/10.1002\/14651858.CD011203.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3263_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12974-020-01847-9","volume":"17","author":"W Gilmore","year":"2020","unstructured":"Gilmore W, et al. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis. J Neuroinflamm. 2020;17(1):189.","journal-title":"J Neuroinflamm"},{"key":"3263_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/DDDT.S32687","volume":"7","author":"JW Brown","year":"2013","unstructured":"Brown JW, Coles AJ. Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis. Drug Des Devel Ther. 2013;7:131\u20138.","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"3263_CR8","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1093\/brain\/awac064","volume":"145","author":"T Ruck","year":"2022","unstructured":"Ruck T, et al. Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity. Brain. 2022;145(5):1711\u201325.","journal-title":"Brain"},{"key":"3263_CR9","doi-asserted-by":"publisher","first-page":"175628642095411","DOI":"10.1177\/1756286420954119","volume":"13","author":"R Alroughani","year":"2020","unstructured":"Alroughani R, et al. The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective. Ther Adv Neurol Disord. 2020;13:1756286420954119.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"3263_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13075-022-02761-6","volume":"24","author":"S Gopaluni","year":"2022","unstructured":"Gopaluni S, et al. Alemtuzumab for refractory primary systemic vasculitis-a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE). Arthritis Res Ther. 2022;24(1):81.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"3263_CR11","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3324\/haematol.2010.036152","volume":"96","author":"K Hodgson","year":"2011","unstructured":"Hodgson K, et al. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica. 2011;96(5):752\u201361.","journal-title":"Haematologica"},{"key":"3263_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/2055217320933928","author":"SM Yap","year":"2020","unstructured":"Yap SM, et al. Alemtuzumab-related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onset. Multiple Scler J Exp Transl Clin. 2020; https:\/\/doi.org\/10.1177\/2055217320933928.","journal-title":"Multiple Scler J Exp Transl Clin"},{"issue":"1","key":"3263_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1352458518816612","volume":"26","author":"A Cuker","year":"2020","unstructured":"Cuker A, et al. Immune thrombocytopenia in alemtuzumab-treated MS patients: incidence, detection, and management. Mult Scler J. 2020;26(1):48\u201356.","journal-title":"Mult Scler J"},{"issue":"3","key":"3263_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s13730-023-00822-6","volume":"13","author":"SM Leibowitz","year":"2024","unstructured":"Leibowitz SM, et al. A case of relapsing anti-GBM disease secondary to alemtuzumab therapy. CEN Case Rep. 2024;13(3):209\u201314.","journal-title":"CEN Case Rep"},{"issue":"6","key":"3263_CR15","doi-asserted-by":"publisher","first-page":"e868","DOI":"10.1212\/NXI.0000000000000868","volume":"7","author":"E Meltzer","year":"2020","unstructured":"Meltzer E, et al. Mitigating alemtuzumab-associated autoimmunity in MS: a \u201cwhack-a-mole\u201d B-cell depletion strategy. Neurol Neuroimmunol Neuroinflamm. 2020;7(6):e868.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"3263_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fendo.2017.00254","volume":"8","author":"M Rotondi","year":"2017","unstructured":"Rotondi M, et al. Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: an example of selective anti-TSH-receptor immune response. Front Endocrinol (Lausanne). 2017;8:254.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"3263_CR17","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1212\/NXI.0000000000000516","volume":"6","author":"JK Chan","year":"2019","unstructured":"Chan JK, Traboulsee AL, Sayao AL. Case of alemtuzumab-related alopecia areata management in MS. Neurol Neuroimmunol Neuroinflamm. 2019;6(1):e516.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"14","key":"3263_CR18","doi-asserted-by":"publisher","first-page":"7338","DOI":"10.3390\/ijerph18147338","volume":"18","author":"G Borriello","year":"2021","unstructured":"Borriello G, Ianniello A, Toosy AT. Alopecia universalis occurring after alemtuzumab treatment for multiple sclerosis. A two-year follow-up of two patients. Int J Environ Res Public Health. 2021;18(14):7338.","journal-title":"Int J Environ Res Public Health"},{"issue":"24","key":"3263_CR19","doi-asserted-by":"publisher","first-page":"e2233","DOI":"10.1212\/WNL.0000000000006648","volume":"91","author":"T Ruck","year":"2018","unstructured":"Ruck T, et al. Vitiligo after alemtuzumab treatment: secondary autoimmunity is not all about B cells. Neurology. 2018;91(24):e2233\u20137.","journal-title":"Neurology"},{"key":"3263_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103511","author":"S Arnett","year":"2022","unstructured":"Arnett S, et al. Low vitamin D levels do not predict risk of autoimmune disease following alemtuzumab treatment for multiple sclerosis. Multiple Scler Relat Disord. 2022. https:\/\/doi.org\/10.1016\/j.msard.2022.103511.","journal-title":"Multiple Scler Relat Disord"},{"issue":"7","key":"3263_CR21","first-page":"2052","volume":"119","author":"JL Jones","year":"2009","unstructured":"Jones JL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Investig. 2009;119(7):2052\u201361.","journal-title":"J Clin Investig"},{"issue":"3","key":"3263_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40263-024-01066-3","volume":"38","author":"L Costa-Frossard Fran\u00e7a","year":"2024","unstructured":"Costa-Frossard Fran\u00e7a L, et al. Real-world retrospective analysis of alemtuzumab outcomes in relapsing-remitting multiple sclerosis: the LEMCAM study. CNS Drugs. 2024;38(3):231\u20138.","journal-title":"CNS Drugs"},{"key":"3263_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"3263_CR24","unstructured":"Cochrane handbook for systematic reviews of interventions version 6.4. In T.J. Higgins JPT, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Chichester, United Kingdom: Cochrane; 2023. Available from www.training.cochrane.org\/handbook."},{"issue":"3","key":"3263_CR25","doi-asserted-by":"publisher","first-page":"378","DOI":"10.11124\/JBIES-23-00268","volume":"22","author":"TH Barker","year":"2024","unstructured":"Barker TH, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies. JBI Evid Synth. 2024;22(3):378\u201388.","journal-title":"JBI Evid Synth"},{"issue":"3","key":"3263_CR26","first-page":"494","volume":"21","author":"TH Barker","year":"2023","unstructured":"Barker TH, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synth. 2023;21(3):494\u2013506.","journal-title":"JBI Evid Synth"},{"key":"3263_CR27","doi-asserted-by":"crossref","unstructured":"Moola SMZ, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris MZE, editor. JBI manual for evidence synthesis. Adelaide, South Australia: JBI; 2020. Available from: https:\/\/reviewersmanual.joannabriggs.org\/.","DOI":"10.46658\/JBIRM-17-06"},{"issue":"7","key":"3263_CR28","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2013-307042","volume":"85","author":"L Azzopardi","year":"2014","unstructured":"Azzopardi L, et al. Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(7):795\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3263_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125377","author":"AJ Coles","year":"2019","unstructured":"Coles AJ, et al. Keratinocyte growth factor impairs human thymic recovery from lymphopenia. JCI Insight. 2019. https:\/\/doi.org\/10.1172\/jci.insight.125377.","journal-title":"JCI Insight"},{"issue":"9191","key":"3263_CR30","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","volume":"354","author":"AJ Coles","year":"1999","unstructured":"Coles AJ, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354(9191):1691\u20135.","journal-title":"Lancet"},{"issue":"3","key":"3263_CR31","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","volume":"83","author":"GA Hill-Cawthorne","year":"2012","unstructured":"Hill-Cawthorne GA, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(3):298\u2013304.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"50","key":"3263_CR32","doi-asserted-by":"publisher","first-page":"20200","DOI":"10.1073\/pnas.1313654110","volume":"110","author":"JL Jones","year":"2013","unstructured":"Jones JL, et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci U S A. 2013;110(50):20200\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"3263_CR33","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/acn3.50935","volume":"6","author":"CW Keller","year":"2019","unstructured":"Keller CW, et al. Impact of Fc\u03b3R variants on the response to alemtuzumab in multiple sclerosis. Ann Clin Transl Neurol. 2019;6(12):2586\u201394.","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"3263_CR34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/cen.14616","volume":"97","author":"J Manso","year":"2022","unstructured":"Manso J, et al. Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: a real-life and monocentric experience at a tertiary-level centre. Clin Endocrinol. 2022;97(3):331\u20138.","journal-title":"Clin Endocrinol"},{"key":"3263_CR35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ebiom.2019.07.062","volume":"46","author":"T Ruck","year":"2019","unstructured":"Ruck T, et al. Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: a prospective cohort study. EBioMedicine. 2019;46:381\u20136.","journal-title":"EBioMedicine"},{"key":"3263_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1137665","author":"S Sandgren","year":"2023","unstructured":"Sandgren S, et al. The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: a nationwide prospective survey. Front Neurol. 2023. https:\/\/doi.org\/10.3389\/fneur.2023.1137665.","journal-title":"Front Neurol"},{"key":"3263_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577759","author":"AG Vakrakou","year":"2021","unstructured":"Vakrakou AG, et al. IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients. J Neuroimmunol. 2021.\u00a0https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577759.","journal-title":"J Neuroimmunol"},{"key":"3263_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1249201","author":"MR von Essen","year":"2023","unstructured":"von Essen MR, et al. Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control. Front Immunol. 2023; https:\/\/doi.org\/10.3389\/fimmu.2023.1249201.","journal-title":"Front Immunol"},{"key":"3263_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.760546","author":"PE Walo-Delgado","year":"2021","unstructured":"Walo-Delgado PE, et al. Role of B cell profile for predicting secondary autoimmunity in patients treated with alemtuzumab. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.760546.","journal-title":"Front Immunol"},{"issue":"1","key":"3263_CR40","doi-asserted-by":"publisher","first-page":"e635","DOI":"10.1212\/NXI.0000000000000635","volume":"7","author":"H Wiendl","year":"2020","unstructured":"Wiendl H, et al. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab. Neurol Neuroimmunol Neuroinflamm. 2020;7(1):e635.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"3263_CR41","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1089\/thy.2018.0232","volume":"28","author":"I Muller","year":"2018","unstructured":"Muller I, et al. Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy: evidence that TRAb may precede thyroid dysfunction by many years. Thyroid. 2018;28(12):1682\u201393.","journal-title":"Thyroid"},{"key":"3263_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110266","author":"Z Sabahi","year":"2023","unstructured":"Sabahi Z, et al. A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis. Int Immunopharmacol. 2023; https:\/\/doi.org\/10.1016\/j.intimp.2023.110266.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"3263_CR43","doi-asserted-by":"publisher","first-page":"16414","DOI":"10.3390\/ijms160716414","volume":"16","author":"T Ruck","year":"2015","unstructured":"Ruck T, et al. Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci. 2015;16(7):16414\u201339.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"3263_CR44","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3390\/cells12141875","volume":"12","author":"JP Robinson","year":"2023","unstructured":"Robinson JP, et al. Flow cytometry: the next revolution. Cells. 2023;12(14):1875.","journal-title":"Cells"},{"issue":"1","key":"3263_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/adt.2010.0308","volume":"9","author":"CB Black","year":"2011","unstructured":"Black CB, et al. Cell-based screening using high-throughput flow cytometry. Assay Drug Dev Technol. 2011;9(1):13\u201320.","journal-title":"Assay Drug Dev Technol"},{"key":"3263_CR46","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231194823","author":"AJ Coles","year":"2023","unstructured":"Coles AJ, et al. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study. Ther Adv Neurol Disord. 2023; https:\/\/doi.org\/10.1177\/17562864231194823.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"3263_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40120-017-0086-4","volume":"7","author":"MB Sintzel","year":"2018","unstructured":"Sintzel MB, Rametta M, Reder AT. Vitamin D and multiple sclerosis: a comprehensive review. Neurol Ther. 2018;7(1):59\u201385.","journal-title":"Neurol Ther"},{"issue":"3","key":"3263_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12016-011-8255-1","volume":"42","author":"A Antico","year":"2012","unstructured":"Antico A, et al. Hypovitaminosis D as predisposing factor for atrophic type A gastritis: a case-control study and review of the literature on the interaction of Vitamin D with the immune system. Clin Rev Allergy Immunol. 2012;42(3):355\u201364.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"3263_CR49","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jaad.2012.01.040","volume":"67","author":"J Orgaz-Molina","year":"2012","unstructured":"Orgaz-Molina J, et al. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: a case-control study. J Am Acad Dermatol. 2012;67(5):931\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"3263_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.574967","author":"R Zhao","year":"2021","unstructured":"Zhao R, et al. Immunomodulatory function of vitamin D and its role in autoimmune thyroid disease. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.574967.","journal-title":"Front Immunol"},{"key":"3263_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103781","author":"HK Goischke","year":"2022","unstructured":"Goischke HK. Prevention or reduction of alemtuzumab-induced secondary autoimmune diseases through high-dose daily vitamin D supplementation? Mult Scler Relat Disord. 2022. https:\/\/doi.org\/10.1016\/j.msard.2022.103781.","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"3263_CR52","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","volume":"74","author":"D Baker","year":"2017","unstructured":"Baker D, et al. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol. 2017;74(8):961\u20139.","journal-title":"JAMA Neurol"},{"key":"3263_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.798300","author":"J Massey","year":"2022","unstructured":"Massey J, et al. Haematopoietic stem cell transplantation results in extensive remodelling of the clonal T cell repertoire in multiple sclerosis. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.798300.","journal-title":"Front Immunol"},{"issue":"3","key":"3263_CR54","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1172\/JCI71691","volume":"124","author":"PA Muraro","year":"2014","unstructured":"Muraro PA, et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest. 2014;124(3):1168\u201372.","journal-title":"J Clin Invest"},{"issue":"9","key":"3263_CR55","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/jnnp-2020-325304","volume":"92","author":"S Pfeuffer","year":"2021","unstructured":"Pfeuffer S, et al. Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab. J Neurol Neurosurg Psychiatry. 2021;92(9):1007\u201313.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-024-03263-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-024-03263-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-024-03263-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T08:04:13Z","timestamp":1732003453000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-024-03263-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3263"],"URL":"https:\/\/doi.org\/10.1186\/s12974-024-03263-9","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"10 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This systematic review utilised existing published data and did not directly involve the recruitment of participants therefore no consent was required. The authors also advise that there are no other ethical conflicts relating to this research project to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors wish to declare that SJS and SAB are investigators on the RAMBLE trial (ACTRN12621001502820). The RAMBLE study has been funded by MS Australia (Project Grant 21-2-060). SAB has received support through Griffith University in relation to service on advisory boards, conference organising committees and speakers honoraria from Novartis, Roche and Alexion, and has been a principal investigator on clinical trials sponsored by ATARA, Biogen-Idec, Sanofi and UCB. RM, NEF, and SMG declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"281"}}